Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Final Salvo? Galvus Infringement Case Simmers In India

Executive Summary

Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.

You may also be interested in...



Novartis Galvus India Case: Wockhardt Pulls Back?

Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.

India 'refuses' to progress Novartis Galvumet patent application

The Indian patent office has declined to "proceed further" with Novartis' application for vildagliptin and metformin in a single formulation (Galvumet) citing lack of inventive step and objections around the "sufficiency of disclosure".

Novartis strikes against four more Indian Galvus copiers

Pre-emptive intellectual property rights-related legal action appears to be on the uptick in India with Novartis now moving the Delhi High Court against four more Indian firms alleging infringement of its patent concerning the DPP-4 inhibitor for diabetes, vildagliptin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel